{"id":962024,"date":"2026-05-13T07:16:25","date_gmt":"2026-05-13T11:16:25","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-8\/"},"modified":"2026-05-13T07:16:25","modified_gmt":"2026-05-13T11:16:25","slug":"nurix-therapeutics-to-participate-in-upcoming-investor-conferences-8","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-8\/","title":{"rendered":"Nurix Therapeutics to Participate in Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p>BRISBANE, Calif., May  13, 2026  (GLOBE NEWSWIRE) &#8212; Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will participate in fireside chats at the following investor conferences:<\/p>\n<ul type=\"disc\">\n<li>\n          <strong>RBC Global Healthcare Conference<\/strong><br \/>\n          <br \/>Wednesday, May 20, 2026, at 1:30 p.m. ET.<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>\n          <strong>Jefferies Global Healthcare Conference<\/strong><br \/>\n          <br \/>Wednesday, June 3, 2026, at 11:05 a.m. ET.<\/li>\n<\/ul>\n<p>The fireside chats will be webcast live and may be viewed via a link in the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=u81ENFU0mNIjVo9DEWv47ZvU8ExCpcBxSgAcUhZRehrCjh-BFQhO3FDzirwcpcuR1xUtr4P4vYoN9DMDYUB7mFSoLpicyjB67Pl4_QtJ3I4=\" rel=\"nofollow\" target=\"_blank\">Investors<\/a> section of the Nurix website. The archived webcasts will be available for 30 days after the event.<\/p>\n<p>\n        <strong>About Nurix Therapeutics, Inc.<\/strong><br \/>\n        <br \/>Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Nurix\u2019s wholly owned, clinical stage pipeline includes degraders of Bruton\u2019s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix also is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Nurix\u2019s partnered drug discovery pipeline consists of a preclinical stage degrader of STAT6 in collaboration with Sanofi, a clinical stage degrader of IRAK4 in collaboration with Gilead, as well as multiple additional programs under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix\u2019s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine\u2019s next chapter with a new script to outmatch disease. Nurix is headquartered in Brisbane, California. For additional information visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CgUcP79yWLBp7iA9GYjQVWjRzc61zx7qyI1RFSlKkphWHKk-mwk1wpWhJm1QjVdPprt4iRJzD998Jfn4D1vq1_BxoNmPDTxmQAiA0Cs11YY=\" rel=\"nofollow\" target=\"_blank\">http:\/\/www.nurixtx.com<\/a>.<\/p>\n<p>\n        <strong>Contacts:<\/strong>\n      <\/p>\n<p>\n        <strong>Investors<\/strong><br \/>\n        <br \/>Kris Fortner<br \/>Nurix Therapeutics, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=f-LaF9fAbcgUbMl-dIKEluzChC0JX4-yfX9BP4b8ZITC419hiDwCEi8LVQiuRtHZYhS6X8REifpYmG2QzuhThv4VkeVMrS43hKIkjxpQ9MY=\" rel=\"nofollow\" target=\"_blank\">kfortner@nurixtx.com<\/a><\/p>\n<p>Sylvia Wheeler<br \/>Wheelhouse Life Science Advisors<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bPwPnQHVgxL6LPSPY51QTiBCWd9y6cT3bB-SGAJCCeXG_Tu2MJcJ5fq1rAztrbLq31pg7jETLtXO5-HaANv4YevjF86DUkj-aGRNd8J4-q3haVJE4tU5ddeGSWQ2R4sM\" rel=\"nofollow\" target=\"_blank\">swheeler@wheelhouselsa.com<\/a><\/p>\n<p>\n        <strong>Media<\/strong><br \/>\n        <br \/>Aljanae Reynolds<br \/>Wheelhouse Life Science Advisors<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vthwtyD3SrWXA05za4-mP6g47S75UIhIk4M94krumizyPPFm11WCZnnPGcCiIdRc4_UqaFLrpG6uNSGZy4gqIqWkxznRHSqUB2Ar252GHlt8U61s_4-X8BcUNawkWInv5SX9Neoq4MreyRU55GEyeqxPHqzSpI1074_zuB-aLuRosSX_uvsnc-LNHoHgB5z_rzp7J95jI0JzyY1TqNdTgcV3n18Cvgkewiq-4rWeckMinDYk0AJrND6KrTh8DvvI-zhZAa9vcQ4NYPQZoQKgGsGF0PnCW7NiFDHefJxebVahw9AwL2rmwBtlOR2tzitK\" rel=\"nofollow\" target=\"_blank\">areynolds@wheelhouselsa.com<\/a><\/p>\n<p>Kris Fortner<br \/>Nurix Therapeutics, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3l_yKt20pomdb2rL1WBAPt4lrKrIb6oZByKumDzJ4hnOMjHPWU84G2TuIpw9b1Z0nN_iZfvSCb9hRPgHVcylbYPU16ujbc9qBccQd0OXxWI=\" rel=\"nofollow\" target=\"_blank\">Kfortner@nurixtx.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxODk2NCM3NTk5NzI4IzIyMDA2Njk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MGYyOTg5YjEtYmI0Zi00ZDNlLWE1MGEtMjI5OWJhMzYzNjA0LTEyMTIyMjItMjAyNi0wNS0xMy1lbg==\/tiny\/Nurix-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BRISBANE, Calif., May 13, 2026 (GLOBE NEWSWIRE) &#8212; Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will participate in fireside chats at the following investor conferences: RBC Global Healthcare Conference Wednesday, May 20, 2026, at 1:30 p.m. ET. Jefferies Global Healthcare Conference Wednesday, June 3, 2026, at 11:05 a.m. ET. The fireside chats will be webcast live and may be viewed via a link in the Investors section of the Nurix website. The archived webcasts will be available for 30 days after the event. About Nurix Therapeutics, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-8\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Nurix Therapeutics to Participate in Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-962024","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nurix Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-8\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nurix Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BRISBANE, Calif., May 13, 2026 (GLOBE NEWSWIRE) &#8212; Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will participate in fireside chats at the following investor conferences: RBC Global Healthcare Conference Wednesday, May 20, 2026, at 1:30 p.m. ET. Jefferies Global Healthcare Conference Wednesday, June 3, 2026, at 11:05 a.m. ET. The fireside chats will be webcast live and may be viewed via a link in the Investors section of the Nurix website. The archived webcasts will be available for 30 days after the event. About Nurix Therapeutics, &hellip; Continue reading &quot;Nurix Therapeutics to Participate in Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-8\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-13T11:16:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxODk2NCM3NTk5NzI4IzIyMDA2Njk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-8\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-8\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Nurix Therapeutics to Participate in Upcoming Investor Conferences\",\"datePublished\":\"2026-05-13T11:16:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-8\\\/\"},\"wordCount\":404,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-8\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxODk2NCM3NTk5NzI4IzIyMDA2Njk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-8\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-8\\\/\",\"name\":\"Nurix Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-8\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-8\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxODk2NCM3NTk5NzI4IzIyMDA2Njk=\",\"datePublished\":\"2026-05-13T11:16:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-8\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-8\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-8\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxODk2NCM3NTk5NzI4IzIyMDA2Njk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxODk2NCM3NTk5NzI4IzIyMDA2Njk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-8\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nurix Therapeutics to Participate in Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nurix Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-8\/","og_locale":"en_US","og_type":"article","og_title":"Nurix Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk","og_description":"BRISBANE, Calif., May 13, 2026 (GLOBE NEWSWIRE) &#8212; Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will participate in fireside chats at the following investor conferences: RBC Global Healthcare Conference Wednesday, May 20, 2026, at 1:30 p.m. ET. Jefferies Global Healthcare Conference Wednesday, June 3, 2026, at 11:05 a.m. ET. The fireside chats will be webcast live and may be viewed via a link in the Investors section of the Nurix website. The archived webcasts will be available for 30 days after the event. About Nurix Therapeutics, &hellip; Continue reading \"Nurix Therapeutics to Participate in Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-8\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-13T11:16:25+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxODk2NCM3NTk5NzI4IzIyMDA2Njk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-8\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-8\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Nurix Therapeutics to Participate in Upcoming Investor Conferences","datePublished":"2026-05-13T11:16:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-8\/"},"wordCount":404,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-8\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxODk2NCM3NTk5NzI4IzIyMDA2Njk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-8\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-8\/","name":"Nurix Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-8\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-8\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxODk2NCM3NTk5NzI4IzIyMDA2Njk=","datePublished":"2026-05-13T11:16:25+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-8\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-8\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-8\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxODk2NCM3NTk5NzI4IzIyMDA2Njk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxODk2NCM3NTk5NzI4IzIyMDA2Njk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nurix-therapeutics-to-participate-in-upcoming-investor-conferences-8\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Nurix Therapeutics to Participate in Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/962024","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=962024"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/962024\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=962024"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=962024"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=962024"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}